Big money was evident throughout the 36th J.P. Morgan Healthcare Conference — from the $200 an hour it costs to meet with someone in some hotel lobbies or lounges to the price of drugs. But as life-changing, one-shot-and-you're-done gene therapies emerge as options — with price tags approaching or exceeding $1 million — how much is too much?
Mir Imran developed an early defibrillator and those full-body scanners at airport security. After a career that's also included patents for medical devices, his Rani Therapeutics now is taking on new-age drugs designed to reduce side effects and increase efficacy.
Dale Schenk was the backbone of Prothena Corp. as the South San Francisco company as it built an impressive portfolio of drugs in a few years, including three that are in four clinical trials today. Then pancreatic cancer killed him. Current Prothena President and CEO Gene Kinney talks about the company and the impact of Schenk's death and life.
Atul Butte, the director of the Institute of Computational Health Sciences at the University of California, San Francisco, talks about demystifying machine learning and artificial intelligence and aggregating data to produce more-efficient clinical trials.
Max Bronstein, the chief advocacy and science policy officer at the EveryLife Foundation for Rare Diseases, talks about how increasing newborn screening and developing new screening tests can help patients and drug companies as well as lower the health care bill.
Bill Anderson on Jan. 1 became CEO of biotech pioneer Genentech Inc. We talked to him as part of our annual Biotech Forum about issues ranging from cancer immunotherapy, drug pricing and lessons learned at Genentech since 2006.
NetSuite founder Evan Goldberg's personal journey with mutant, cancer-causing BRCA genes led to the seeding a year ago of the BRCA Foundation, aimed at helping people get tested and pushing scientists toward new findings.
AirXpanders developed and is selling a device that uses carbon dioxide — think bike tire inflators — to expand tissue in preparation for breast reconstruction surgery. Listen to how it came to be and where the Palo Alto company is going.
Experimental one shot-and-you’re-done fixes to gene mutations are moving forward into the clinic. But there still lots of big questions around gene therapy. We talk to Matt Patterson, the founder and CEO of Audentes Therapeutics Inc., a San Francisco company that will be taking three gene therapies into clinical trials this year and found a surprising answer to one of the emerging field’s most pressing questions.
Lynn Seely oversaw development of a blockbuster prostate cancer drug as chief medical officer at Medivation, but when she left the biotech company and job offers started flowing in, not a single one was for a CEO job. Learn to how Seely landed the CEO job at Myovant Sciences and why more women are needed in corner offices and board rooms.